

# C24

## Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions



This guideline provides definitions, principles, and approaches to laboratory quality control design, implementation, and assessment.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

# Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions

Curtis A. Parvin, PhD  
Nils B. Person, PhD, FACB  
Nikola Baumann, PhD  
Lili Duan, PhD  
A. Paul Durham  
Valerio M. Genta, MD  
Jeremie Gras, MD  
Greg Miller, PhD  
Megan E. Sawchuk, MT(ASCP)

## Abstract

Clinical and Laboratory Standards Institute guideline C24—*Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions* discusses the principles of statistical QC, with particular attention to the planning of a QC strategy and the application of statistical QC in a medical laboratory. Although these principles are of interest to manufacturers, this guideline is intended for use by medical laboratory personnel in order to provide a QC strategy that uses control materials that are external to a reagent kit, instrument, or measuring system and that are intended to simulate the measurement of a patient specimen.

Clinical and Laboratory Standards Institute (CLSI). *Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions*. 4th ed. CLSI guideline C24 (ISBN 1-56238-946-7 [Print]; ISBN 1-56238-947-5 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2016 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions*. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.

### **Previous Editions:**

March 1985, September 1986, May 1991, February 1999, June 2006

## Committee Membership

### Consensus Council

**Carl D. Mottram, RRT, RPFT,**  
**FAARC**  
**Chairholder**  
**Mayo Clinic**  
**USA**

J. Rex Astles, PhD, FACB, DABCC  
 Centers for Disease Control and  
 Prevention  
 USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
 DLM; CQA(ASQ)CMQ/OE  
 Laboratories Made Better!  
 USA

Karen W. Dyer, MT(ASCP), DLM  
 Centers for Medicare & Medicaid  
 Services  
 USA

Dennis J. Ernst, MT(ASCP),  
 NCPT(NCCT)  
 Center for Phlebotomy Education  
 USA

Thomas R. Fritsche, MD, PhD, FCAP,  
 FIDSA  
 Marshfield Clinic  
 USA

Mary Lou Gantzer, PhD, FACB  
 BioCore Diagnostics  
 USA

Loralie J. Langman, PhD  
 Mayo Clinic  
 USA

Joseph Passarelli  
 Roche Diagnostics Corporation  
 USA

James F. Pierson-Perry  
 Siemens Healthcare Diagnostics Inc.  
 USA

Andrew Quintenz  
 Bio-Rad Laboratories, Inc.  
 USA

Robert Rej, PhD  
 New York State Department of  
 Health – Wadsworth Center  
 USA

Zivana Tezak, PhD  
 FDA Center for Devices and  
 Radiological Health  
 USA

### Document Development Committee on Statistical QC for Clinical Chemistry

**Curtis A. Parvin, PhD**  
**Chairholder**  
**Bio-Rad Laboratories, Inc.**  
**USA**

**Nils B. Person, PhD, FACB**  
**Vice-Chairholder**  
**Siemens Healthcare Diagnostics, Inc.**  
**USA**

Nikola Baumann, PhD  
 Mayo Clinic  
 USA

#### Staff

Clinical and Laboratory Standards  
 Institute  
 USA

Luann Ochs, MS  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Lili Duan, PhD  
 FDA Center for Devices and Radiological  
 Health  
 USA

Jeremie Gras, MD  
 Clinique St. Luc  
 Belgium

Joanne P. Christopher, MA, ELS  
*Editor*

Laura Martin  
*Editor*

Michael A. Russell, MA  
*Editor*

Greg Miller, PhD  
 Virginia Commonwealth University  
 Health System  
 USA

Megan E. Sawchuk, MT(ASCP)  
 Centers for Disease Control and  
 Prevention  
 USA

## **Acknowledgment for the Expert Panel on Clinical Chemistry and Toxicology**

CLSI, the Consensus Council, and the Document Development Committee on Statistical QC for Clinical Chemistry gratefully acknowledge the Expert Panel on Clinical Chemistry and Toxicology for serving as technical advisors and subject matter experts during the development of this guideline.

### **Expert Panel on Clinical Chemistry and Toxicology**

**Johanna Camara, PhD**  
**Chairholder**  
**National Institute of Standards and Technology**  
USA

**Lorin M. Bachmann, PhD, DABCC**  
**Vice-Chairholder**  
**Virginia Commonwealth University Health System**  
USA

Karl De Vore  
Bio-Rad Laboratories, Inc.  
USA

Lili Duan, PhD  
FDA Center for Devices and Radiological Health  
USA

Kamisha Johnson-Davis, PhD,  
DABCC, FACB  
University of Utah and ARUP  
Laboratories  
USA

Gregory T. Maine, PhD, FACB  
Abbott  
USA

Godwin Ogbonna, PhD  
Ortho-Clinical Diagnostics, Inc.  
USA

Curtis Oleschuk, PhD, FCACB  
Diagnostic Services of Manitoba  
Canada

David B. Sacks, MB, ChB, FRCPath  
National Institutes of Health  
USA

### **Acknowledgment**

CLSI, the Consensus Council, and the Document Development Committee on Statistical QC for Clinical Chemistry gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

A. Paul Durham  
APD Consulting  
USA

Valerio M. Genta, MD  
Sentara Virginia Beach General Hospital  
USA

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
Chapter 1: Introduction.....	1
1.1    Scope.....	1
1.2    Background.....	2
1.3    Standard Precautions.....	2
1.4    Terminology.....	3
Chapter 2: Path of Workflow.....	9
Chapter 3: Purpose of Statistical Quality Control.....	11
3.1    Quality Control and Patient Risk.....	11
3.2    Quality Requirements.....	12
3.3    Method Performance Relative to Quality Requirements.....	14
3.4    Types of Out-of-Control Conditions.....	17
3.5    Quality Control Rules.....	17
Chapter 4: Assessing Quality Control Performance.....	19
4.1    False Rejection Rate.....	19
4.2    Detection of Out-of-Control Conditions.....	20
Chapter 5: Planning a Statistical Quality Control Strategy.....	23
5.1    Define the Quality Requirements.....	23
5.2    Select Control Materials.....	24
5.3    Determine Target Values and Standard Deviations for Quality Control Materials That Represent Stable Analytical Performance.....	27
5.4    Set Goals for Quality Control Performance.....	31
5.5    Select a Quality Control Strategy Based on Performance Goals.....	32
5.6    Design a Quality Control Strategy for Multiple Instruments.....	37
Chapter 6: Recovering From an Out-of-Control Condition.....	39
6.1    Responding to an Out-of-Control Quality Control Event.....	39
6.2    Responding to an Out-of-Control Condition.....	39
6.3    Identifying and Correcting Reported Erroneous Patient Results.....	39
Chapter 7: Ongoing Assessment of Quality Control Programs.....	41
7.1    Assessment of the Internal Quality Control Program.....	41
7.2    Using Interlaboratory Quality Control to Assess a Quality Control Program.....	41
Chapter 8: Worked Examples.....	43
8.1    Define the Quality Requirement.....	43
8.2    Select Quality Control Materials.....	43
8.3    Determine Target Values and Standard Deviations.....	43
8.4    Select Quality Control Strategy.....	44
Chapter 9: Conclusion.....	46
Chapter 10: Supplemental Information.....	46
References.....	47

**Contents (Continued)**

Appendix A. Levey-Jennings Chart.....	50
Appendix B. Medical Laboratory Quality Control Shift and Trend Troubleshooting Checklist .....	55
The Quality Management System Approach .....	60
Related CLSI Reference Materials .....	61

## Foreword

The medical laboratory community has used C24, now in its fourth edition, for more than 20 years. Today, statistical QC is still critically important to ensure the quality of the results of any laboratory measurement procedure. The almost universal applicability of statistical QC to quantitative measurement procedures provides laboratories with an essential quality management tool that can be used to monitor the effects of many instrument, reagent, environment, and operator variables on the outcome of a measurement process.

The laboratory director is generally responsible for the laboratory QC program. The definition of quality requirements for the tests being performed is particularly important because laboratory managers, supervisors, scientists, and quality specialists often use those quality requirements to select and validate appropriate measurement and control procedures. C24's approach provides medical laboratory scientists with practical guidance on how to satisfy recommendations by authorities and/or accreditation organizations.<sup>1</sup>

The concepts, approaches, and practices discussed in this guideline are interdependent and all should be carefully studied and considered when developing the specific QC strategy for any measurement procedure, system, or laboratory. C24 highlights the technical issues that need a careful scientific approach to designing, implementing, and assessing QC strategies in order for laboratories to achieve the quality requirements needed by the physicians and patients they serve.

## Overview of Changes

This guideline replaces the previous edition of the approved guideline, C24-A3, published in 2006. The fourth edition maintains the focus on principles and approaches to laboratory QC design, implementation, and assessment that reflect the realities of the modern medical laboratory and its role within the health care enterprise. Several changes were made in this edition, including:

- The alignment of principles and definitions to be consistent with and to supplement the general patient risk model described in CLSI document EP23<sup>TM2</sup>
- The introduction of additional performance measures useful for evaluating the performance characteristics of a QC strategy (see Chapter 5)
- Expanded guidance on setting target values and SDs for QC materials (see Subchapter 5.3)
- A greater focus on QC frequency and QC schedules as a critical part of a QC strategy (see Subchapter 5.5)
- A substantive chapter on recovering from an out-of-control condition (see Chapter 6), including sections on:
  - Responding to an out-of-control QC event
  - Responding to an out-of-control condition
  - Identifying and correcting reported erroneous patient results

**NOTE:** The content of this guideline is supported by the CLSI consensus process, and does not necessarily reflect the views of any single individual or organization.

## Key Words

Patient risk, quality control, quality control plan, quality control rules, quality control strategy, quality requirements, Sigma metric



# Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions

## Chapter 1: Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

### 1.1 Scope

This guideline explains the purpose of statistical QC for quantitative measurement procedures, describes an approach for planning a QC strategy for a particular measurement procedure, describes the use of QC material and QC data, and provides examples that demonstrate a practical QC planning process for medical laboratories.

The recommendations for establishing and maintaining a statistical QC strategy are applicable to quantitative laboratory measurement procedures in all fields of laboratory medicine for which stable control materials can be measured in the same manner as patient specimens. The intended users of this guideline include those responsible for designing, implementing, and using QC, ie, medical laboratory scientists.

This guideline does **not**:

- Describe built-in control mechanisms that might be part of a measuring system, or qualitative or semiquantitative measurement procedures.
- Define specific QC strategies that are appropriate for an individual device or technology.
- Describe alternatives to statistical process control, eg, real-time patient-based QC.
- Consider specific legal requirements that may impose different philosophies or procedures on QC practices (eg, a specific approach for defining quality requirements, specific values for quality requirements, a specific procedure for determining target values for control materials, or a frequency and number of QC measurements) defined by government regulation in a specific country or region.

Additionally, there are types of random errors that may affect measurements performed on individual specimens, rather than a whole group of specimens, and those errors are not detected by a statistical QC strategy. Such errors may be due to the specific design of a measuring system (eg, effect of specimen

viscosity, carryover from a previous specimen, or specimen-specific interferences) or possible operator errors that affect individual specimens, as well as preexamination errors of specimen preparation, storage, and transportation. Special QC strategies may be needed to monitor known special vulnerabilities that relate to a particular device or system design.

## 1.2 Background

Statistical QC strategies are implemented to monitor a measurement procedure's performance to detect any change relative to stable baseline analytical performance. When the actual performance deviates from the expected model, the QC strategy is designed to alert the laboratorian to a change that may affect medical decision making and potentially lead to incorrect treatment, delays in treatment, or patient harm. Designing an effective QC strategy entails determining the magnitude of the change in performance that compromises the usefulness of the measurement procedure results.

There is abundant literature explaining the theoretical and practical bases for initiating and maintaining QC strategies in clinical chemistry<sup>3-9</sup>; however, the routine practice of statistical QC depends on understanding how to:

- Plan QC strategies based on the performance of the measurement procedure and the performance needed to support the intended medical use of the results, including selecting appropriate control materials, establishing the expected values for those control materials, determining when to evaluate controls, and identifying the control rules to determine acceptable performance.
- Implement QC strategies to identify situations when a measurement procedure may not be providing results that are suitable for use in medical decisions.
- Respond to out-of-control situations.

The prevalence of a broad range of automated medical laboratory instruments using widely different measuring principles has complicated the terminology and the steps necessary for establishing QC strategies. There are some highly automated systems that can perform specific, built-in checks that help detect potential problems and alert the operator to instrument malfunction. However, the benefit of statistical QC using samples intended to simulate measurement of patient specimens is that it monitors the outcome of many of the variables and steps that occur in the entire measurement procedure.

## 1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.<sup>10</sup> For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.<sup>11</sup>